港股異動 | 恆安國際(1044.HK)高開6.55%領漲恆指 獲多家機構看好
格隆匯9月16日丨恆安國際(1044.HK)高開6.55%,暫領漲恆指成份股,帶動恆指漲約10點,現報62.65港元,暫成交1462萬港元,最新總市值745億港元。大摩曾發報告指,上調公司2020至2022年的經營溢利預測5-7%,以反映上半年公司毛利率及經營溢利表現強勁,此外相信亦將受惠木漿成本較低,加上產品及定價持續改善,毛利率表現強勁,同時亦將淨利預測升1-3%。將目標價升至83港元,維持“增持”評級。麥格理亦指,相信恆安國際第二季度強勁的銷售勢頭及經營利潤率擴張可繼續延續至下半年,分別上調公司今明兩年盈利預測1%及4%,予目標價87港元,評級“跑贏大市”。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.